With the recent advances in immune checkpoint inhibitors for the treatment of bladder cancer, comprehending the role of RHOJ in immune modulation could yield valuable insights for optimizing immunotherapy strategies. This evidence concerns the gene RHOJ and urinary bladder cancer.